CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
RecruitingPHASE1PHASE2
For patients in the US & Europe
When treatment runs out at home, it may not be over.
A growing number of patients from the US and Europe are reaching remission through CAR-T trials in China — often for a fraction of what it costs at home, and years before these therapies are approved where they live. We help you find out whether a trial could fit you.
▸ source: clinicaltrials.gov · recruiting in China
296CAR-T cell therapy trials recruiting
12Proton therapy trials recruiting
Counts refresh from the public registry every 12 hours.
You may have seen the coverage
Independent reporting on why patients are travelling to China — and what they're finding. These are journalists' accounts, linked in full, not testimonials from us.
BBC World Service
An Australian myeloma patient's cancer became undetectable weeks after CAR-T treatment in Shanghai; she is now in remission back home.
Read the report ↗Business Standard
A New Zealand man told to consider palliative care travelled to China for a CAR-T trial; the total cost, flights included, was around a tenth of prices elsewhere.
Read the report ↗Inside Precision Medicine
In 2025 China approved the world's first CAR-T therapy for a solid tumour, a milestone the field had chased for years.
Read the report ↗Recruiting now: CAR-T cell therapy
A live sample of blood-cancer and solid-tumor cell-therapy studies enrolling patients across Chinese centers. Open any study for eligibility criteria and location.
A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
RecruitingNA
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
RecruitingPHASE1
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
RecruitingPHASE1
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
RecruitingPHASE1
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
RecruitingPHASE2
How CancerTrialMatch works
You stay in control the whole way. Nothing is booked, and no records are shared, without your say-so.
STEP ONE
Tell us your situation
Share the diagnosis, treatments tried, and where you live — in the chat or the form below.
STEP TWO
We match trials
Coordinators cross-check your history against recruiting trials and confirm openings with the hospital.
STEP THREE
Remote record review
The trial team reviews your records remotely and decides whether you may be eligible. No travel yet.
STEP FOUR
Plan the visit
If accepted, you get an invitation letter plus help with visas, translation, and logistics.
Why patients look to China
A fraction of the cost
In the US, a single CAR-T infusion can run $300,000–$475,000. In China it is often around $150,000 — and new therapies are pushing prices lower still.
A field that's proven itself
China approved the world's first solid-tumour CAR-T in 2025, and therapies first developed there have gone on to win FDA approval — a sign of how far the science has come.
When you've been told to wait
For patients who've exhausted approved options, or face long waits at home, a trial can open a door in weeks rather than months.
Get a free eligibility review
Tell us a little about the diagnosis and we'll come back within 24 hours with the trials worth exploring — or an honest "not yet." No cost, no obligation, and you can stop at any point.
Prefer to just ask questions first? Open the chat with Nora in the bottom corner.
We share your details only with vetted treatment coordinators to check trial eligibility. No spam. See our privacy note.